Doctors track new MS Drug's staying power in real patients
NCT ID NCT05811416
Summary
This study observes how long people with relapsing-remitting multiple sclerosis (MS) continue taking a medication called ozanimod in everyday clinic settings. It involves 200 patients in Spain who are new to MS treatment and have low-to-moderate disease activity. The main goal is to see how many patients stay on the drug for two years and to measure its effects on relapses, disability, and thinking skills.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Barcelona, 08008, Spain
Conditions
Explore the condition pages connected to this study.